PepGen Inc.

1.61
-0.01 (-0.62%)
At close: Apr 23, 2025, 3:59 PM
-0.62%
Bid 1.54
Market Cap 52.63M
Revenue (ttm) n/a
Net Income (ttm) -89.98M
EPS (ttm) -2.85
PE Ratio (ttm) -0.56
Forward PE -0.63
Analyst Buy
Ask 1.58
Volume 250,037
Avg. Volume (20D) 2,880,904
Open 1.66
Previous Close 1.62
Day's Range 1.50 - 1.72
52-Week Range 0.88 - 19.30
Beta 1.42

About PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2022
Employees 81
Stock Exchange NASDAQ
Ticker Symbol PEPG
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 645.34% from the latest price.

Stock Forecasts
1 month ago
+67.15%
PepGen shares are trading higher after the company... Unlock content with Pro Subscription
2 months ago
-21.74%
PepGen shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $26 to $16.